Data from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
Authors:
- Patricia LoRussoPLPatricia LoRusso
- Noboru YamamotoNYNoboru Yamamoto
- Manish R. PatelMPManish R. Patel
- Scott A. LaurieSLScott A. Laurie
- Todd M. BauerTBTodd M. Bauer
- Junxian GengJGJunxian Geng
- Teffany DavenportTDTeffany Davenport
- Michael TeufelMTMichael Teufel
- Jian LiJLJian Li
- Mehdi LahmarMLMehdi Lahmar
- Mrinal M. GounderMGMrinal M. Gounder
Open Access
- 11 December 2025
- other
- Published by American Association for Cancer Research (AACR)